期刊文献+

肾细胞癌脆性组氨酸三联体FHIT蛋白表达缺失的临床病理意义 被引量:3

Clinicopathological significance of loss of expression of fragile histidine triad expression in renal cell cancer
下载PDF
导出
摘要 目的:探讨肾细胞癌中脆性组氨酸三联体(fragile histidine triad,FHIT)基因蛋白表达状况及其与临床病理的关系。方法:采用兔抗人FHIT蛋白抗体和枸橼酸-微波-SP免疫组化方法检测86例肾细胞癌、52例癌旁组织和10例肾组织中FHIT的表达状况,并分析其与组织学分级、临床分期以及5年生存率的关系。结果:肾细胞癌FHIT表达较癌旁组织和正常肾组织明显降低,H=69·421,P=0·000。FHIT蛋白表达在肾癌组织学分型(H=11·557,P=0·003)、分级(H=13·402,P=0·001)及临床分期(H=18·168,P=0·000)中差异均有统计学意义。FHIT蛋白表达强阳性组患者5年生存率显著高于弱阳性及阴性组,Z=-2·390,P=0·017。结论:FHIT低表达或缺失可能提示其抑癌功能丧失,对肾细胞癌的发生和演化具有重要作用。FHIT表达缺失可能成为辅助肾细胞癌诊断及预后的一个新标记。肿瘤防治杂志,2005,12(19) OBJECTIVE: To investigate the expression of fragile histidine triad (FHIT) gene protein, and the possible relationship between FHIT expression and clinicopathologieal indices in renal cell carcinoma. METHODS: FHIT protein expression was detected in 86 renal cell carcinomas,52 adjacent non-neoplastic tissues and 10 normal kidney tissues formalin-fixed, paraffin-embedded tissues by the citratemicrowave-SP immunohistochemical method, and the relationship between it and histological grade, clinical stage and 5-year survival rate was analysed RESULTS: Thirty paint two percent (26/86) of renal cell carcinomas, 100. 0% (52/52) of parameoplastie tissues and 100.0% (10/10) of normal kidney tissues showed a strongly positive staining pattern of FHIT protein. There was a significant difference in FHIT expression between carcinomas and adjacent non-neoplastic tissues or normal kidney, H = 69. 421, P = 0. 000. Carcinomas with decreased expression of FHIT were corresponding to the histological type ( H= 11. 557, P=0.003), histological grade (H=13.402, P=0.001), clinical stage (H=18. 168, P=0.000) and 5-year survival rate (Z= -2. 390, P=0.017), respectively. CONCLUSION: The loss of expression of FHIT may be associated with the carcinogenesis of tubule epithelia, the development and the prognosis of the tumor, thus may become a new adjunct diagnostic and prognostic marker in renal cell carcinoma.
出处 《肿瘤防治杂志》 2005年第19期1486-1488,共3页 China Journal of Cancer Prevention and Treatment
关键词 肾细胞/治疗 肾肿瘤/病理学 免疫学试验 存活率 carcinoma, renal cell/therapy kidney neoplasms/pathology immunologic tests survival rate
  • 相关文献

参考文献10

  • 1赵坡,许红民,李晓瑛,王德文,毛新,李维华.肾细胞癌P53、c-erbB-2癌蛋白高表达与预后的关系[J].中华泌尿外科杂志,1995,16(8):457-459. 被引量:6
  • 2Huebner K, Croce C M. Cancer and the FRA3B/FHIT fragile locus: it's a HIT[J]. Br J Cancer,2003,88(10):1501-1506.
  • 3Pekarsky Y, Zanesi N, Palamarchuk A, et al. F HIT: from gene discovery to cancer treatment and prevention[J]. Lancet Oncol,2002,3(12) :748-754.
  • 4Hao X P, Willis J E, Pretlow T G, et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions[J]. Cancer Res,2000,60(1) :18-21.
  • 5Yuan B Z, Keck-Waggoner C, Zimonjic D B, et al. Alterations of the FHIT gene in human hepatocellular cell carcinoma [J].Cancer Res,2000,60(4) :1049-1053.
  • 6赵坡,吕亚莉,钟梅,陈乐真.卵巢癌端粒酶逆转录酶和脆性三联组氨酸蛋白表达的临床病理分析[J].肿瘤防治杂志,2004,11(12):1278-1281. 被引量:3
  • 7Ramp U, Caliskan E, Ebert T, et al. FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival[J]. J Pathol,2002,196(4): 430-436.
  • 8Eyzaguirre E J,Miettinen M, Norris B A,et al, Different immunohistochemical patterns of Fhit protein expression in renal neoplasms[J]. Mod Pathol,1999,12(10) :979-983.
  • 9RosaiJ(回允中主译).阿克曼外科病理学[M].沈阳:辽宁教育出版社,1999.1145-1150,2605-2606.
  • 10Fromowitz F B, Bard R H. Clinical implications of pathologic subtypes in renal cell carcinoma[J]. Semin Urol, 1990,8 (1):31-50.

二级参考文献11

  • 1高冬霞,吕彧,吕英志,马彩红,王玉萍,张波,廖松林.端粒酶转录酶及其调节相关蛋白与增殖细胞核抗原在卵巢上皮性肿瘤中的表达及临床意义[J].中华病理学杂志,2003,32(4):319-322. 被引量:3
  • 2Datar R H, Naritoku W Y, Li P, et al. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas[J]. Gynecol Oncol, 1999, 74 (3):338-345.
  • 3Kyo S, Kanaya T, Takakura M, et al. Exression of human telomerase subunits in ovarian malignant and benign tumors[J].Int J Cancer, 1999, 80(6): 804-809
  • 4Huebner K, Croce C M. Cancer and the FRA3B/FHIT fragile locus: it's a HIT[J]. Br J Cancer,2003,88(10): 1501-1506.
  • 5Pekarsky Y, Zanesi N, Palamarchuk A, et al. FHIT: from gene discovery to cancer treatment and prevention[J]. Lancet Oncol, 2002,3(10): 748-754.
  • 6Buttitta F, Marchetti A, Radi O, et al. Evaluation of FHIT gene alterations in ovarian cancer[J]. Br J Cancer, 1998,77(7):1048-1051.
  • 7Ozaki K, Enomoto T, Yoshino K, et al. Impaired FHIT expression characterizes serous ovarian carcinoma[J]. Br J Cancer, 2001,85(2): 247-254.
  • 8Hao X P, Willis J E, Pretlow T G, et al. Loss of Fragile Histidine Triad Expression in colorectal carcinomas and premalignant lesions[J]. Cancer Res, 2000, 60(1): 18-21.
  • 9Chaudhuri AR, Khan I A, Prasad V, et al. The tumor suppressor protein FHIT. A novel interaction with tubulin[J]. J Biol Chem, 1999, 274(34): 24378-24382.
  • 10朱虹光,宋宜.端粒酶的研究进展,存在问题及其在病理学中的应用[J].中华病理学杂志,2000,29(1):58-59. 被引量:6

共引文献7

同被引文献20

  • 1赵坡,吕亚莉,钟梅,陈乐真.卵巢癌端粒酶逆转录酶和脆性三联组氨酸蛋白表达的临床病理分析[J].肿瘤防治杂志,2004,11(12):1278-1281. 被引量:3
  • 2牛志宏,吕家驹,丁克家,李善军.肾母细胞瘤过表达基因和WT1基因在肾癌组织中转录水平的定量研究[J].中华泌尿外科杂志,2006,27(8):533-536. 被引量:6
  • 3Chao Tian,Zong-Guang Zhou,Wen-Jian Meng,Xiao-Feng Sun,Yong-Yang Yu,Li Li,Hong-Zhi Luo,,Lie Yang,Bin Zhou,Jun Gu.Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients[J].World Journal of Gastroenterology,2007,13(28):3878-3882. 被引量:11
  • 4Huebner K, Croce C M. Cancer and the FRA3B/FHIT fragile locus: it's a HIT[J]. BrJ Cancer, 2003, 88(10): 1501-1506.
  • 5Pekarsky Y, Zanesi N, Palamarchuk A, et al. FHIT: from gene discovery to cancer treatment and prevention[J]. Lancet Oncol, 2002, 3(12): 748-754.
  • 6Hao X P,Willis J E,Pretlow T G,et al. Loss of Fragile Histidine Triad Expression in colorectal carcinomas and premalignant lesions[J].Cancer Res, 2000, 60(1): 18-21.
  • 7Yuan B Z, Keck-Waggoner C, Zimonjic D B, et al. Alterations of the FHIT gene in human hepatocellular cell carcinoma[J]. Cancer Res, 2000, 60(4) : 1049-1053.
  • 8Koch E, Fiedler W, Tannapfel A, et al. Alteration of the fragile histidine triad gene in intrahepatic cholangiocarcinoma[J].Eur J Gastroenterol Hepatol, 2003,15 (8) : 907-913.
  • 9Kang Y K, Kim W H, Jang J J. Expression of G1-S modulators (p53, p16, p27, Cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma[J]. Hum Pathol, 2002, 33(9): 877-883.
  • 10Sugimachi K, Aishima S, Taguchi K, et al. The role of overexpression and gene amplification of Cyclin D1 in intrahepatic cholangiocarcinoma[J].J Hepatol, 2001, 35(1): 74-79.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部